Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 510 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Heart Dysfunction Clear all
Completed Phase 4 Interventional Results available

A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.

NCT03456856
View directory record Official record
Conditions
Heart Failure (HF)
Interventions
Ivabradine
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Wilmington, Delaware • Detroit, Michigan • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 27, 2026, 5:27 PM EDT
Withdrawn Phase 2 Interventional

Effects of Nitric Oxide on the Endothelium During Hemolysis.

NCT03748082
View directory record Official record
Conditions
Endothelial Dysfunction, Hemolysis Intravascular, Cardiovascular Diseases, Cardiovascular Risk Factor
Interventions
Nitric Oxide, Reactive Hyperemia Index, Endothelial Cells Collection
Drug · Diagnostic Test · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 27, 2026, 5:27 PM EDT
Completed Phase 1 Interventional

Assessment of Coronary Plaque Composition

NCT01581632
View directory record Official record
Conditions
Coronary Atherosclerosis, Endothelial Dysfunction, Coronary Small Vessel Disease
Interventions
LipiScan/LipiScan IVUS
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 27, 2026, 5:27 PM EDT
Completed Not applicable Interventional Results available

Safety and Performance Study of the INGEVITY Lead

NCT01688843
View directory record Official record
Conditions
Bradycardia, Sinus Node Dysfunction
Interventions
INGEVITY lead
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
44
States / cities
Gilbert, Arizona • Glendale, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 27, 2026, 5:27 PM EDT
Completed Phase 3 Interventional

Correlation of Endothelial Function and Early Coronary Artery Disease in Humans

NCT00271492
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
atrasentan
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 30, 2010 · Synced Oct 27, 2026, 5:27 PM EDT
Completed Not applicable Interventional Results available

Perioperative Multimodal General AnesTHesia Focusing on Specific CNS Targets in Patients Undergoing carDiac surgERies

NCT05279898
View directory record Official record
Conditions
Postoperative Delirium, Hemodynamic Instability, Pain, Neurocognitive Dysfunction
Interventions
EEG Monitoring, Ropivacaine, Ketamine, Remifentanil, Dexmedetomidine, Rocuronium, Propofol
Device · Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
60 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 27, 2026, 5:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Is Dexmedetomidine Associated With a Lower Incidence of Postoperative Delirium When Compared to Propofol or Midazolam in Cardiac Surgery Patients

NCT00417664
View directory record Official record
Conditions
Delirium
Interventions
Dexmedetomidine, Propofol, Midazolam
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 89 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 27, 2026, 5:27 PM EDT
Not listed No phase listed Observational

CarDiac MagnEtic Resonance for Primary Prevention Implantable CardioVerter DebrillAtor ThErapy: an International Registry (DERIVATE)

NCT03352648
View directory record Official record
Conditions
Heart Failure, Left Ventricular Systolic Dysfunction
Interventions
Not listed
Lead sponsor
Gianluca Pontone, MD, PhD
Other
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 27, 2026, 5:27 PM EDT
Recruiting No phase listed Observational

Assessing the Relationship Between Symptoms and Mitral Regurgitnant. Severity

NCT06738615
View directory record Official record
Conditions
Mitral Insufficiency
Interventions
Pressure volume loop evaluation, cardiovascular magnetic resonance imaging, Cardiopulmonary exercise testing (CPET), Kansas City Cardiomyopathy Questionairre
Diagnostic Test
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 27, 2026, 5:27 PM EDT
Completed Not applicable Interventional

Effects of Almonds on Vascular Reactivity in Patients With Coronary Artery Disease

NCT00782015
View directory record Official record
Conditions
Vascular Disease, Endothelial Dysfunction, Heart Disease, Cardiovascular Diseases, Hypertension
Interventions
Almonds, Placebo Comparator:
Dietary Supplement
Lead sponsor
Tufts University
Other
Eligibility
20 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 27, 2026, 5:27 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Development of a Novel Stress Testing Protocol to Define the Relationship Between Coronary Microvascular Dysfunction and Diastology in Women With Angina But No Evidence of Obstructive Coronary Artery Disease

NCT02301663
View directory record Official record
Conditions
Microvascular Coronary Dysfunction
Interventions
Handgrip, Altitude simulation, Leg exercise
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 27, 2026, 5:27 PM EDT
Recruiting Phase 1 Interventional

Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)

NCT06600178
View directory record Official record
Conditions
Angina Patients With Non-obstructive Coronary Artery Disease, Coronary Microvascular Disease, Coronary Microvascular Dysfunction (CMD)
Interventions
Brenzavvy (bexagliflozin), 20 mg Oral Tablet, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 27, 2026, 5:27 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the Safety and Effectiveness of the OPTIMIZER System in Subjects With Heart Failure: FIX-HF-5

NCT00112125
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
OPTIMIZER System
Device
Lead sponsor
Impulse Dynamics
Industry
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 27, 2026, 5:27 PM EDT
Completed Phase 3 Interventional

Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction

NCT00998218
View directory record Official record
Conditions
Sudden Cardiac Death, Ventricular Arrythmias
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Aspirus Heart and Vascular Institute-Research and Education
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Wausau, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 9, 2012 · Synced Oct 27, 2026, 5:27 PM EDT
Completed No phase listed Observational

Novel Single Wave Assessment in Measuring Cardiac Dysfunction and Metabolic Syndrome in Patients With Cancer

NCT04014231
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Diagnostic Imaging, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 27, 2026, 5:27 PM EDT
Completed Phase 4 Interventional Results available

Octaplas Pediatric Plasma Replacement Trial

NCT02050841
View directory record Official record
Conditions
Liver Surgery, Liver Dysfunction, Coagulopathy, Cardiac Surgery
Interventions
octaplas
Biological
Lead sponsor
Octapharma
Industry
Eligibility
Up to 16 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • Atlanta, Georgia • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2020 · Synced Oct 27, 2026, 5:27 PM EDT
Completed No phase listed Observational

Predicting the Development of Myocardial Depression in Acute Neurological Patients

NCT03801694
View directory record Official record
Conditions
Myocardial Depression, Takotsubo Syndrome, Subarachnoid Hemorrhage, Acute Ischemic Stroke
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
50 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 27, 2026, 5:27 PM EDT
Withdrawn Phase 1Phase 2 Interventional

The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.

NCT02503280
View directory record Official record
Conditions
Chronic Ischemic Left Ventricular Dysfunction, Myocardial Infarction
Interventions
Autologous hMSCs, Autologous Human C-Kit CSCs II, Placebo, Biosense Webster MyoStar NOGA Injection Catheter System
Drug · Device
Lead sponsor
Joshua M Hare
Other
Eligibility
21 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 27, 2026, 5:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions

NCT01953523
View directory record Official record
Conditions
Neurodegenerative Diseases, Osteoarthritis, Erectile Dysfunction, Autoimmune Diseases, Cardiomyopathies, Emphysema
Interventions
Administration of autologous adipose derived SVF
Procedure
Lead sponsor
Elliot Lander
Industry
Eligibility
16 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rancho Mirage, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 27, 2026, 5:27 PM EDT
Completed Not applicable Interventional

Prospective Aerobic Reconditioning Intervention Study

NCT01113840
View directory record Official record
Conditions
Heart Failure
Interventions
Exercise, Control
Behavioral
Lead sponsor
Wake Forest University
Other
Eligibility
60 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 27, 2026, 5:27 PM EDT
Completed No phase listed Observational

Characterization of the Plasma Proteome Following Left Ventricular Assist Device Implantation

NCT02428894
View directory record Official record
Conditions
Ventricular Dysfunction, Left
Interventions
LVAD
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 27, 2026, 5:27 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ATI-105 in Healthy Adults

NCT07869654
View directory record Official record
Conditions
Friedreich Ataxia, Cardiomyopathies, Central Nervous System Diseases, Neuromuscular Diseases, Mitochondrial Diseases, Mitochondrial Dysfunction, Genetic Disease
Interventions
ATI-105, Placebo
Drug
Lead sponsor
Adjuvia Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 27, 2026, 5:27 PM EDT
Completed No phase listed Observational

Self-management and Cognitive Function in Adults With Heart Failure

NCT01461629
View directory record Official record
Conditions
Cognitive Impairment, Cardiac Disease, Heart Failure
Interventions
Not listed
Lead sponsor
Kent State University
Other
Eligibility
55 Years to 85 Years
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Oct 27, 2026, 5:27 PM EDT
Recruiting No phase listed Observational

Ultra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED)

NCT06641362
View directory record Official record
Conditions
Bradycardia, Heart Failure, Ventricular Dysfunction
Interventions
Ultra High Frequency Electrocardiogram (UHF-ECG)
Device
Lead sponsor
VDI Technologies
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Avondale, Arizona • Mesa, Arizona • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 27, 2026, 5:27 PM EDT